SCHEMBL19008878

SCHEMBL19008878

CC1(C)c2ccccc2-c2cnc(-c3ccc(-c4nc(-c5ccccc5)cc(-c5ccccc5)n4)c4ccccc34)nc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.38
▸ KMT2A Q03164 6/20 0.38
▸ SMN1; SMN2 Q16637 5/20 0.35
▸ MAPT P10636 4/20 0.35
▸ TDP1 Q9NUW8 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ MAPK10 P53779 1/20 0.35
▸ TSHR P16473 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ ATM Q13315 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ PDGFRB P09619 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ FLT3 P36888 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ HPGD P15428 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19008897 0.93 MEN1 (0.38) MEN1KMT2ASMN1; SMN2MAPTTDP1
SCHEMBL19008908 0.91 CYP19A1 (0.35) MEN1KMT2ASMN1; SMN2MAPTTDP1
SCHEMBL19008873 0.90 TSHR (0.37) MEN1KMT2ASMN1; SMN2MAPTTDP1
SCHEMBL19008902 0.90 PDK2 (0.36) MEN1KMT2AACACA
SCHEMBL19008870 0.89 MEN1 (0.34) MEN1KMT2ASMN1; SMN2MAPTTDP1
SCHEMBL19008864 0.88 MEN1 (0.36) MEN1KMT2ASMN1; SMN2MAPTTDP1
SCHEMBL19008884 0.88 MEN1 (0.43) MEN1KMT2ASMN1; SMN2MAPTTDP1
SCHEMBL19008853 0.86 MEN1 (0.42) MEN1KMT2ASMN1; SMN2MAPTTDP1
SCHEMBL19008857 0.86 MEN1 (0.40) MEN1KMT2ASMN1; SMN2MAPTTDP1
SCHEMBL19008860 0.85 NPC1 (0.33) MEN1KMT2ASMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10461262-B2 Condensed cyclic compound and an organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2019-10-29 — — US disclosed
US-20170179408-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2017-06-22 — — US disclosed
US-20170179408-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2017-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10461262-B2 Condensed cyclic compound and an organic light-emitting device including the same CRY1, CRY2, CCNA1 MEN1 389/4885KMT2A 2042/4885SMN1; SMN2 4406/4885
US-20170179408-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CRY2, CCNA1 MEN1 389/4885KMT2A 2042/4885SMN1; SMN2 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback